샘플 요청 목록

 카트 문의
시장보고서
상품코드
1793894

조직 기반 게놈 프로파일링 시장

Tissue-based Genomic Profiling
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 386 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 조직 기반 게놈 프로파일링 시장은 2030년까지 19억 달러에 달할 전망

2024년에 14억 달러로 추정되는 세계의 조직 기반 게놈 프로파일링 시장은 2024-2030년에 CAGR 5.0%로 성장하며, 2030년에는 19억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 시퀀스 기술은 CAGR 5.4%를 기록하며, 분석 기간 종료까지 12억 달러에 달할 것으로 예측됩니다. 면역조직화학 분야의 성장률은 분석 기간 중 CAGR 3.9%로 추정됩니다.

미국 시장은 3억 8,640만 달러로 추정, 중국은 CAGR 7.9%로 성장 예측

미국의 조직 기반 게놈 프로파일링 시장은 2024년에는 3억 8,640만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 분석 기간인 2024-2030년 CAGR을 7.9%로, 2030년까지 3억 7,690만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 2.4%와 5.0%로 예측됩니다. 유럽에서는 독일이 CAGR 3.2%로 성장할 것으로 예측됩니다.

세계의 조직 기반 게놈 프로파일링 시장 - 주요 동향과 촉진요인 정리

조직 기반 유전체 프로파일링이 정밀 종양학의 새로운 시대를 열 것인가?

조직 기반 유전체 프로파일링(TGP)은 포르말린 고정 파라핀 포매(FFPE) 또는 신선한 조직 샘플 분석을 통해 고형 종양의 유전적 변화를 식별할 수 있게 함으로써 맞춤형 의료의 혁신적 툴로 등장했습니다. 이를 통해 종양 전문의는 종양에 특이적인 유전체 변화를 기반으로 환자를 표적치료제나 면역치료에 맞출 수 있으며, 치료 결과를 개선하고 불필요한 치료를 최소화할 수 있습니다. TGP는 현재 진단과 치료법 선택뿐만 아니라 예후 평가와 내성 기전 모니터링에 도움을 주며 정밀 종양학의 중심이 되고 있습니다.

이 방법은 특히 폐암, 유방암, 대장암, 전립선암 등 임상 종양학 진료와 암 연구에 널리 사용되고 있습니다. 차세대 염기서열분석(NGS)을 이용한 단일 유전자 분석과 종합적인 패널을 모두 지원하며, 수백 개의 암 관련 유전자 전체의 변이, 증폭, 융합을 동시에 분석할 수 있습니다. 임상 가이드라인이 바이오마커 중심의 치료 결정을 권장함에 따라 조직 기반 유전체 프로파일링은 틈새 진단 옵션에서 치료법 선택과 임상시험 등록을 위한 최전방 툴로 진화하고 있습니다.

NGS와 바이오인포매틱스의 발전은 어떻게 임상적 유용성을 높이고 있는가?

기술의 발전은 TGP의 능력과 정밀도를 크게 확장하고 있습니다. 고처리량 NGS 플랫폼은 저품질 또는 제한된 조직 샘플에서도 높은 민감도와 특이성을 가진 초심도 시퀀싱을 가능하게 합니다. 라이브러리 준비 키트, 하이브리드 캡처 기술, PCR 기반 농축의 개선으로 이전에는 검출할 수 없었던 희귀하고 복잡한 변이체를 포함하여 임상적으로 관련된 돌연변이에 대한 커버리지가 향상되고 있습니다. 또한 납기 또한 개선되고 있으며, 이 기술을 일상 임상에서 사용할 수 있게 되었습니다.

바이오인포매틱스의 병행적인 발전은 데이터 분석에 혁명을 가져오고 있습니다. 클라우드 기반 파이프라인, AI를 활용한 변종 분류, 통합 임상 데이터베이스를 통해 방대한 유전체 데이터의 신속한 분석과 병원성 및 약물 반응성 주석이 가능해졌습니다. 이 툴들은 또한 유전체, 전사체, 후성유전체 데이터를 통합한 임상 보고를 지원하여 진단의 정확도를 높이고 있습니다. 중요한 것은 실험실에서 FFPE 샘플의 DNA/RNA 무결성을 유지하는 프로토콜을 개발하고 있다는 점입니다. 이러한 발전과 함께 TGP는 고정밀 종양학에서 신뢰할 수 있는 필수적인 자산이 되고 있습니다.

임상적 채택, 동반진단, 상환정책이 접근성을 확대할 수 있는가?

TGP 시장의 가장 강력한 추진력 중 하나는 치료 의사결정 경로에 유전체 데이터가 통합되고 있다는 점입니다. EGFR, ALK, ROS1, BRAF 억제제 등 표적치료제와 함께 승인된 동반진단제들은 현재 많은 경우, 적격성 확인을 위해 조직 기반 유전체 확인이 필요한 경우가 많습니다. 점점 더 많은 항암제가 바이오마커에 의존하게 되면서 검증된 고처리량 유전체 프로파일링 플랫폼에 대한 수요가 증가하고 있습니다. 이와 함께 대학병원과 주요 암 전문 병원에서는 TGP를 종양 진단 및 치료 계획의 루틴으로 채택하고 있습니다.

상환 정책도 진화하고 있습니다. 많은 국가에서 공공 및 민간 보험사가 특정 암종에 대한 종합적인 유전체 프로파일링을 보장하기 시작했으며, 특히 가이드라인에서 권장하는 표적 치료와 관련된 경우 더욱 그러합니다. 규제 당국은 시간이 오래 걸리고 비용 효율성이 떨어지는 순차적 단일 유전자 검사보다 멀티플렉스 패널의 임상적 유용성을 인정하고 있습니다. 병리검사실 교육 및 인프라 투자, 진단업체와 의료기관과의 제휴를 통해 중견병원 및 연구기관에서도 TGP를 이용할 수 있게 되었습니다. 이러한 노력은 접근성을 민주화하고, 암 치료의 진단 불평등을 완화하고 있습니다.

조직 기반 유전체 프로파일링 시장의 세계 성장 동력은 무엇인가?

조직 기반 유전체 프로파일링 시장의 성장은 기술 혁신, 암 치료의 변화, 규제 진화 등 여러 가지 상호 연관된 요인에 의해 주도되고 있습니다. 첫째, 고정밀, 고처리량 NGS 플랫폼의 보급으로 일상적인 생검 샘플에서 강력하고 확장 가능한 유전체 분석이 가능해졌습니다. 둘째, 바이오마커 기반 치료 선택에 대한 임상적 신뢰가 높아지면서 종양 조직에서 직접 얻은 실용적인 유전체 데이터에 대한 수요가 증가하고 있습니다.

셋째, FDA와 EMA가 승인한 동반 진단 및 표적 치료제의 리스트이 확대되면서 조직 기반 유전체 인사이트에 대한 치료 접근성이 향상되고 있습니다. 넷째, 진료비 상승과 국가적 정밀의료 구상의 영향으로 의료비 부담이 줄어들고 표준 치료 프로토콜에 포함되고 있습니다. 다섯째, 조직 처리, 시퀀싱 화학, 데이터 분석 툴의 개선으로 실패율이 감소하고, 까다로운 시료 조건에서도 프로파일링이 가능해졌습니다. 마지막으로 종양학 인프라와 임상연구에 대한 전 세계적인 투자로 인해 바이오제약, 진단기업, 의료기관의 파트너십이 촉진되어 선진국과 신흥 시장 모두에서 TGP의 도입이 가속화되고 있습니다. 이러한 요인들로 인해 조직 기반 유전체 프로파일링은 차세대 암 진단 및 치료제의 핵심으로 자리 잡고 있습니다.

부문

기술(시퀀스 기술, 면역조직화학, 기타 기술), 용도(맞춤형 의료 용도, 종양 진단 용도, 연구 용도), 최종 용도(연구기관 최종 용도, 임상 연구기관 최종 용도, 병원·클리닉 최종 용도, 진단 연구소 최종 용도, 제약·바이오테크놀러지 기업 최종 용도, 기타 최종 용도)

조사 대상 기업의 예

  • Agilent Technologies
  • Bio-Rad Laboratories
  • Biocartis
  • Caris Life Sciences
  • F. Hoffmann-La Roche AG
  • Foundation Medicine(Roche)
  • Guardant Health
  • Illumina, Inc.
  • Invitae Corporation
  • LabCorp(Covance)
  • MDxHealth
  • NanoString Technologies
  • Novogene
  • Personalis, Inc.
  • QIAGEN N.V.
  • Roche Diagnostics
  • SOPHiA GENETICS
  • Thermo Fisher Scientific
  • Veracyte, Inc.
  • WuXi NextCODE

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 일반적인 LLM나 업계별 SLM 쿼리에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 대량 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.08.28

Global Tissue-based Genomic Profiling Market to Reach US$1.9 Billion by 2030

The global market for Tissue-based Genomic Profiling estimated at US$1.4 Billion in the year 2024, is expected to reach US$1.9 Billion by 2030, growing at a CAGR of 5.0% over the analysis period 2024-2030. Sequencing Techniques, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$1.2 Billion by the end of the analysis period. Growth in the Immunohistochemistry segment is estimated at 3.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$386.4 Million While China is Forecast to Grow at 7.9% CAGR

The Tissue-based Genomic Profiling market in the U.S. is estimated at US$386.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$376.9 Million by the year 2030 trailing a CAGR of 7.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.4% and 5.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.

Global Tissue-Based Genomic Profiling Market - Key Trends & Drivers Summarized

Is Tissue-Based Genomic Profiling Ushering in a New Era of Precision Oncology?

Tissue-based genomic profiling (TGP) has emerged as a transformative tool in personalized medicine, enabling the identification of genetic alterations in solid tumors through the analysis of formalin-fixed paraffin-embedded (FFPE) or fresh tissue samples. It allows oncologists to match patients with targeted therapies and immunotherapies based on tumor-specific genomic alterations, improving outcomes and minimizing unnecessary treatments. TGP is now central to precision oncology, aiding not only in diagnosis and therapy selection but also in prognostic evaluation and monitoring resistance mechanisms.

This method is being widely adopted in clinical oncology practices and cancer research, especially for lung, breast, colorectal, and prostate cancers. It supports both single-gene assays and comprehensive panels using next-generation sequencing (NGS), which simultaneously analyzes hundreds of mutations, amplifications, and fusions across cancer-related genes. As clinical guidelines increasingly endorse biomarker-driven treatment decisions, tissue-based genomic profiling is evolving from a niche diagnostic option to a frontline tool for therapy selection and trial enrollment.

How Are Advancements in NGS and Bioinformatics Enhancing Clinical Utility?

Technological advancements are significantly expanding the capabilities and accuracy of TGP. High-throughput NGS platforms now allow for ultra-deep sequencing with high sensitivity and specificity, even from low-quality or limited tissue samples. Improvements in library preparation kits, hybrid capture techniques, and PCR-based enrichment are enhancing coverage of clinically relevant mutations, including rare and complex variants that were previously undetectable. Turnaround times are also improving, making the technology more viable for routine clinical use.

Parallel progress in bioinformatics is revolutionizing data interpretation. Cloud-based pipelines, AI-powered variant classification, and integrated clinical databases enable rapid analysis of vast genomic data and annotation of pathogenicity and drug response. These tools also support the integration of genomic, transcriptomic, and epigenetic data into unified clinical reports, enhancing diagnostic precision. Importantly, laboratories are developing protocols to preserve DNA/RNA integrity from FFPE samples-critical for retrospective and real-world analyses. Together, these advancements are making TGP a reliable and indispensable asset in precision oncology.

Can Clinical Adoption, Companion Diagnostics, and Reimbursement Policies Expand Access?

One of the strongest tailwinds for the TGP market is the rising integration of genomic data into therapeutic decision-making pathways. Companion diagnostics approved alongside targeted drugs-such as EGFR, ALK, ROS1, and BRAF inhibitors-now often require tissue-based genomic confirmation for eligibility. As more cancer drugs become biomarker-dependent, the demand for validated, high-throughput genomic profiling platforms is increasing. In parallel, academic medical centers and leading oncology hospitals are adopting TGP as a routine part of tumor boards and treatment planning.

Reimbursement policies are also evolving. In many countries, public and private payers are beginning to cover comprehensive genomic profiling for select cancer types, particularly when linked to a guideline-recommended targeted therapy. Regulatory bodies are increasingly recognizing the clinical utility of multiplex panels over sequential single-gene tests, which are more time-consuming and less cost-effective. Training and infrastructure investments in pathology labs, as well as partnerships between diagnostic companies and healthcare providers, are expanding the availability of TGP even in mid-tier hospitals and research institutions. These efforts are democratizing access and reducing diagnostic inequities in cancer care.

What Is Driving the Global Growth of the Tissue-Based Genomic Profiling Market?

The growth in the tissue-based genomic profiling market is driven by several interrelated forces stemming from technological innovation, oncology practice transformation, and regulatory evolution. First, the widespread adoption of NGS platforms with high accuracy and throughput is enabling robust, scalable genomic analysis from routine biopsy samples. Second, increasing clinical reliance on biomarker-driven treatment selection is driving demand for actionable genomic data derived directly from tumor tissue.

Third, the expanding list of FDA- and EMA-approved companion diagnostics and targeted therapies is linking therapeutic access directly to tissue-based genomic insights. Fourth, rising reimbursement support and national precision medicine initiatives are improving affordability and integration into standard care protocols. Fifth, improved tissue processing, sequencing chemistry, and data interpretation tools are reducing failure rates and making profiling viable even in challenging sample conditions. Lastly, global investment in oncology infrastructure and clinical research is fostering partnerships between biopharma, diagnostics firms, and healthcare institutions, accelerating the adoption of TGP in both developed and emerging markets. Together, these drivers are firmly positioning tissue-based genomic profiling at the heart of next-generation cancer diagnostics and therapeutics.

SCOPE OF STUDY:

The report analyzes the Tissue-based Genomic Profiling market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Technology (Sequencing Techniques, Immunohistochemistry, Other Technologies); Application (Personalized Medicine Application, Oncological Diagnostics Application, Research Application); End-Use (Research Institutes End-Use, Clinical Research Organizations End-Use, Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • Agilent Technologies
  • Bio-Rad Laboratories
  • Biocartis
  • Caris Life Sciences
  • F. Hoffmann-La Roche AG
  • Foundation Medicine (Roche)
  • Guardant Health
  • Illumina, Inc.
  • Invitae Corporation
  • LabCorp (Covance)
  • MDxHealth
  • NanoString Technologies
  • Novogene
  • Personalis, Inc.
  • QIAGEN N.V.
  • Roche Diagnostics
  • SOPHiA GENETICS
  • Thermo Fisher Scientific
  • Veracyte, Inc.
  • WuXi NextCODE

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Tissue-based Genomic Profiling - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Adoption of Precision Oncology Drives Demand for Tissue-Based Genomic Profiling
    • Expansion of Targeted Therapy Approvals Spurs Need for Biomarker-Driven Diagnostics
    • Increased Use of NGS Platforms in Hospital and Academic Labs Enhances Testing Capacity
    • Growing Emphasis on Tumor Heterogeneity Analysis Fuels Multiplexed Genomic Assay Adoption
    • Integration of Genomic Profiling With Clinical Decision Support Tools Improves Treatment Personalization
    • Wider Insurance Coverage for Companion Diagnostics Expands Accessibility in Oncology Care
    • Increased Inclusion of Genomic Testing in Clinical Trials Strengthens Institutional Demand
    • Technological Advancements in FFPE Sample Processing Improve Assay Accuracy
    • Rising Prevalence of Solid Tumors Supports Market Growth in Breast, Lung, and Colorectal Cancer Segments
    • Adoption of Pan-Cancer Genomic Panels Accelerates Standardization in Diagnostic Workflows
    • Growth in Oncology Centers and Molecular Pathology Labs Drives Test Volume Growth
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Tissue-based Genomic Profiling Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Tissue-based Genomic Profiling by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Tissue-based Genomic Profiling by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Sequencing Techniques by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Sequencing Techniques by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Sequencing Techniques by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Immunohistochemistry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Immunohistochemistry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Immunohistochemistry by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Diagnostic Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Pharma & Biotech Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Clinical Research Organizations End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Clinical Research Organizations End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Clinical Research Organizations End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Personalized Medicine Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Personalized Medicine Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Personalized Medicine Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Oncological Diagnostics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Oncological Diagnostics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: World 16-Year Perspective for Oncological Diagnostics Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Research Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Research Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: World 16-Year Perspective for Research Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Tissue-based Genomic Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: USA 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Canada 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • JAPAN
    • Tissue-based Genomic Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Japan 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • CHINA
    • Tissue-based Genomic Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 68: China Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: China 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: China 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: China 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • EUROPE
    • Tissue-based Genomic Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Tissue-based Genomic Profiling by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Tissue-based Genomic Profiling by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Europe 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • FRANCE
    • Tissue-based Genomic Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 89: France Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: France 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: France 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: France 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • GERMANY
    • Tissue-based Genomic Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Germany 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: Italy 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Tissue-based Genomic Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 116: UK Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: UK 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Spain 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Spain Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Spain 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Russia 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Russia Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Russia 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Rest of Europe 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Tissue-based Genomic Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Tissue-based Genomic Profiling by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Tissue-based Genomic Profiling by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Asia-Pacific 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Tissue-based Genomic Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Australia 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 170: Australia Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Australia Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Australia 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • INDIA
    • Tissue-based Genomic Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 173: India Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: India 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: India 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 179: India Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: India Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: India 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: South Korea 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 188: South Korea Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: South Korea Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: South Korea 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Asia-Pacific Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Asia-Pacific 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Tissue-based Genomic Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Tissue-based Genomic Profiling by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Tissue-based Genomic Profiling by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Latin America 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Latin America Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Latin America 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 217: Argentina 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 218: Argentina Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Argentina Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 220: Argentina 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 226: Brazil 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 227: Brazil Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Brazil Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 229: Brazil 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 235: Mexico 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 236: Mexico Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Mexico Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 238: Mexico 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Latin America Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 247: Rest of Latin America 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Tissue-based Genomic Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Tissue-based Genomic Profiling by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Tissue-based Genomic Profiling by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 256: Middle East 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Middle East Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 259: Middle East 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 265: Iran 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 266: Iran Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Iran Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 268: Iran 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 274: Israel 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 275: Israel Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Israel Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 277: Israel 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Saudi Arabia Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 286: Saudi Arabia 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 292: UAE 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 293: UAE Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: UAE Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 295: UAE 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Middle East Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 304: Rest of Middle East 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • AFRICA
    • Tissue-based Genomic Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 310: Africa 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 311: Africa Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Africa Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 313: Africa 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제